Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 5/20 | 0.46 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762576 | 0.89 | PLK1 (0.64) | FGFR1PLK1EGFRULK1SYK | |
| SCHEMBL3762926 | 0.85 | EGFR (0.50) | PLK1EGFRSYKIGF1RTNK2 | |
| SCHEMBL3760283 | 0.84 | EGFR (0.48) | PLK1EGFRSYKIGF1RTNK2 | |
| SCHEMBL3762506 | 0.80 | ULK1 (0.75) | FGFR1PLK1EGFRULK1SYK | |
| SCHEMBL3771362 | 0.77 | ULK1 (0.61) | FGFR1PLK1EGFRULK1SYK | |
| SCHEMBL3766732 | 0.75 | PLK1 (0.62) | PLK1EGFRULK1IGF1RINSR | |
| SCHEMBL3766371 | 0.75 | PLK1 (0.62) | PLK1EGFRULK1IGF1RINSR | |
| SCHEMBL3756737 | 0.74 | PLK1 (0.61) | PLK1EGFRULK1IGF1RINSR | |
| SCHEMBL3766662 | 0.73 | PLK1 (0.60) | FGFR1PLK1EGFRULK1SYK | |
| SCHEMBL3764381 | 0.73 | EGFR (0.48) | FGFR1EGFRSYKIGF1RTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | claimed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | claimed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | FGFR1 7/4885PLK1 60/4885EGFR 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.